Prosecution Insights
Prosecution Insights
66 pending office actions • 35 clients • 65 examiners • 43 art units • 0 of 66 (0%) have an AI response strategy ready • 73 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 29 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 29 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (3%) |
| §103 only | 28 (42%) |
| §102 only | 12 (18%) |
| §112 only | 9 (14%) |
| Double-patenting only | 7 (11%) |
| Double-patenting + other | 2 (3%) |
| No statute on record | 6 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PATTERSON, SARAH COOPER | 2 | 58.8% | +57.9% |
| BRAZIN, JACQUELINE | 1 | 66.0% | +53.3% |
| LAMPRECHT, JOEL | 1 | 81.3% | +16.9% |
| SCHLIENTZ, LEAH H | 1 | 41.9% | +38.9% |
| TIWARI, VYOMA SHUBHAM | 1 | 30.2% | +46.7% |
| SEITZ, ANTHONY JOSEPH | 1 | 67.0% | +26.9% |
| ROGERS, ERIC JASON | 1 | 57.8% | +30.0% |
| SILVERMAN, SETH ADAM | 1 | 73.2% | +13.6% |
| CHESTNUT, BARRY A | 1 | 73.5% | +6.1% |
| OLSON, ANDREA STEFFEL | 1 | 62.3% | -12.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19202992 | Methods for Biomedical Targeting and Delivery and Devices and Systems for Practicing the Same | LAMPRECHT, JOEL | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18158396 | GENE EXPRESSION PROFILES TO PREDICT BREAST CANCER OUTCOMES | YU, TIAN NMN | 27d |
| 18275170 | Methods for Pulmonary Function Testing With Machine Learning Analysis and Systems for Same | HANEY, JONATHAN MICHAEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17490516 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | PATTERSON, SARAH COOPER | 72d overdue |
| 18863312 | Nanoparticles for Delivery of Nucleic Acid Cargos | SCHLIENTZ, LEAH H | 25d overdue |
| 18658264 | Methods for Representing Data Analysis and Systems for Same | SILVERMAN, SETH ADAM | 12d |
| 17642089 | ANTI-ONCOLYTIC VIRUS ANTIGEN ANTIBODIES AND METHODS OF USING SAME | PATTERSON, SARAH COOPER | 46d |
| 19372053 | Untitled | BRAZIN, JACQUELINE | — |
| 19202992 | Methods for Biomedical Targeting and Delivery and Devices and Systems for Practicing the Same | LAMPRECHT, JOEL | — |
| 18912410 | METHODS OF TREATING EGFRVIII EXPRESSING GLIOBLASTOMAS | TIWARI, VYOMA SHUBHAM | — |
| 18833616 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | SEITZ, ANTHONY JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1626 | 3 |
| 3791 | 3 |
| 1622 | 3 |
| 1675 | 3 |
| 3798 | 2 |
| 1616 | 2 |
| 1647 | 2 |
| 1643 | 2 |
| 1641 | 2 |
| 1658 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19372053 | Untitled | The Regents of the University of California | BRAZIN, JACQUELINE | 1798 | — | Final Rejection | — | Pending | |
| 19202992 | Methods for Biomedical Targeting and Delivery and Devices and Systems for Practicing the Same | The Regents of the University of California | LAMPRECHT, JOEL | 3798 | DP | Non-Final OA | — | Pending | May 08, 2025 |
| 18863312 | Nanoparticles for Delivery of Nucleic Acid Cargos | 4Basebio UK Ltd. | SCHLIENTZ, LEAH H | 1618 | §103 | Final Rejection | 25d overdue | Pending | Nov 05, 2024 |
| 18912410 | METHODS OF TREATING EGFRVIII EXPRESSING GLIOBLASTOMAS | The Regents of the University of California | TIWARI, VYOMA SHUBHAM | — | Non-Final OA | — | Pending | Oct 10, 2024 | |
| 18833616 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | Genase Therapeutics B.V. | SEITZ, ANTHONY JOSEPH | DP | Non-Final OA | — | Pending | Jul 26, 2024 | |
| 18728983 | Recombinant Cell Line Expressing Membrane Proteins and Vesicles Prepared Therefrom | Exocure Sweden AB | ROGERS, ERIC JASON | 1699 | §102 | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18658264 | Methods for Representing Data Analysis and Systems for Same | The Regents of the University of California | SILVERMAN, SETH ADAM | 2172 | §103 | Non-Final OA | 12d | Pending | May 08, 2024 |
| 18682740 | Vaccine Antigen | Macfarlane Burnet Institute For Medical Research And Public Health Limited | CHESTNUT, BARRY A | §102 | Non-Final OA | — | Pending | Feb 09, 2024 | |
| 18433142 | NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS | Koranex Capital | OLSON, ANDREA STEFFEL | 1693 | DPOther | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18294487 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERHIDROSIS | Wayne Stephen Andrews | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 39d | Pending | Feb 01, 2024 |
| 18580417 | Methods and Model Systems for Assessing Therapeutic Properties of Candidate Agents and Related Computer Readable Media and Systems | The Regents of the University of California | BARRON, SEAN C | 1682 | §102 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18395150 | Vaccine Therapy | Ac Immune SA | FONTAINHAS, AURORA M | 1649 | DP | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18573978 | Anti-CCR8 Antibodies and Uses Thereof | Nanjing Immunophage Biotech Co., Ltd. | DRISCOLL, MAUREEN VARINA | §112 | Non-Final OA | — | Pending | Dec 22, 2023 | |
| 18563357 | HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR, AND PREPARATION THEREFOR AND USE THEREOF IN TREATMENT | Shanghai Kechow Pharma, Inc. | SAEED, KAMAL A | 1626 | §102 | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18561981 | Methods And Devices For Real-Time Word And Speech Decoding From Neural Activity | The Regents of the University of California | PADDA, ARI SINGH KANE | 3791 | §103 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18384266 | WATER DISPERSIBLE GRANULE ACYLHYDRAZONE APYRASE INHIBITOR FORMULATION | Texas Crop Science, Inc. | VIGIL, TORIANA NICHOLE | 1612 | §103 | Final Rejection | — | Pending | Oct 26, 2023 |
| 18384286 | ANTIFUNGAL COMPOSITIONS AND METHODS FOR THEIR USE | Texas Crop Science, Inc. | HIRT, ERIN E | 1616 | Other | Non-Final OA | 21d | Pending | Oct 26, 2023 |
| 18382419 | SUSPENSION CONCENTRATE ACYLHYDRAZONE APYRASE INHIBITOR FORMULATION | Texas Crop Science, Inc. | ARMSTRONG, SUSANNAH SIPPLE | 1616 | DP | Final Rejection | 113d overdue | Pending | Oct 20, 2023 |
| 18287565 | Immunoglobulin Cleaving Enzyme | Genovis AB | BERKE-SCHLESSEL, DAVID W | 1651 | §112 | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18285814 | Thermally Stable Vaccine Formulations Utilising Metal Organic Framework (MOF) Shells | Commonwealth Scientific And Industrial Research Organisation | PARK, HAEJIN S | 1614 | §102 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18551502 | Pharmaceutical Combinations for Treating Cancer | T3 Pharmaceuticals AG | BUTTICE, AUDREY L | 1647 | Other | Non-Final OA | 42d | Pending | Sep 20, 2023 |
| 18278719 | ASSEMBLED THREE-DIMENSIONAL CULTURES OF HUMAN NEURONS AND GLIA AND THEIR USE | The Regents of the University of California | TICHY, JENNIFER M.H. | 1653 | §103 | Non-Final OA | — | Pending | Aug 24, 2023 |
| 18278377 | CONDITIONAL DEGRADATION OF PROTEINS THAT ARE LOCALIZED AT THE PLASMA MEMBRANE | The Regents of the University of California | NICKOL, GARY B | 1643 | §102 | Non-Final OA | — | Pending | Aug 22, 2023 |
| 18547139 | Oncolytic Virus and Methods of Use | NorthShore University HealthSystem | WANG, RUIXUE | 1672 | §112 | Final Rejection | — | Pending | Aug 18, 2023 |
| 18275170 | Methods for Pulmonary Function Testing With Machine Learning Analysis and Systems for Same | The Regents of the University of California | HANEY, JONATHAN MICHAEL | 3791 | §101 | Final Rejection | — | Pending | Jul 31, 2023 |
| 18274152 | Genetically Modified Hepatocyte Populations | Cytotheryx, Inc. | YU, MISOOK | 1641 | §103 | Non-Final OA | 84d | Pending | Jul 25, 2023 |
| 18222436 | METHOD AND APPARATUS FOR REDUCING EXCESS PRESSURE IN ISOCHORIC SYSTEMS | Biochoric, Inc. | KOSAR, AARON J | 1655 | §103 | Non-Final OA | — | Pending | Jul 15, 2023 |
| 18271663 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | Sichuan Gooddoctor Panxi Pharmaceutical Co., Ltd. | NIEBAUER, RONALD T | 1658 | §102 | Non-Final OA | 60d | Pending | Jul 10, 2023 |
| 18210515 | Magnesium Threonate Compositions and Uses Thereof | Neurocentria, Inc. | SOROUSH, LAYLA | 1622 | DP | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18205215 | RNA VIRUS INHIBITOR COMPOUNDS WITH IMPROVED METABOLIC STABILITY AND USES THEREOF | The Governors of the University of Alberta | KUCKLA, ANNA GRACE | 1626 | §103 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18265171 | Biliary Delivery Methods, Compositions and Kits for Use Therein | Ambys Medicines, Inc. | ROSENTHAL, ANDREW S | 1613 | §103 | Final Rejection | 61d | Pending | Jun 02, 2023 |
| 18036844 | Hypoimmunogenic Biotherapeutics | The Scripps Research Institute | LEWIS, PATRICK T | 1691 | §103 | Non-Final OA | — | Pending | May 12, 2023 |
| 18036133 | CLUBROOT RESISTANCE IN RAPESEED BRASSICA NAPUS | Npz Innovation GmbH | WILLIAMS, KEITH RICHARD | 1663 | §103 | Non-Final OA | 210d overdue | Pending | May 09, 2023 |
| 18034045 | CONTROLLING CELLULAR BEHAVIOR USING FEED-FORWARD CIRCUITS | The Regents of the University of California | NICOL, ALEXANDER W | 1634 | §102 | Non-Final OA | 19d | Pending | Apr 26, 2023 |
| 18030662 | ENGINEERED CELLULAR ADHESION MOLECULES AND METHODS OF USE THEREOF | The Regents of the University of California | SHUPE, ELIZABETH A | 1643 | §103 | Final Rejection | — | Pending | Apr 06, 2023 |
| 18020611 | TARGETED PROTEIN DEGRADATION IN THERAPEUTIC CELLS | The Regents of the University of California | BELYAVSKYI, MICHAIL A | 1644 | DP | Final Rejection | 8d overdue | Pending | Feb 09, 2023 |
| 18107265 | MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | Cue Biopharma, Inc. | HUYNH, PHUONG N | 1641 | §103 | Non-Final OA | 30d overdue | Pending | Feb 08, 2023 |
| 18158396 | GENE EXPRESSION PROFILES TO PREDICT BREAST CANCER OUTCOMES | British Columbia Cancer Agency Branch | YU, TIAN NMN | 1681 | §101 | Final Rejection | 27d | Pending | Jan 23, 2023 |
| 18015309 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. | YOO, SUN JAE | 1621 | §102 | Final Rejection | 39d | Pending | Jan 09, 2023 |
| 18014846 | Immunogenic Compounds | Ac Immune SA | GURLEY, JAMI MICHELLE | 1647 | §112 | Final Rejection | — | Pending | Jan 06, 2023 |
| 18009688 | USE OF PHYTOCANNABINOIDS FOR TREATING MULTIPLE MYELOMA | Entourage Biosciences Inc. | HAVLIN, ROBERT H | 1626 | §103 | Final Rejection | 74d overdue | Pending | Dec 09, 2022 |
| 17999842 | PI3K GAMMA INHIBITOR PEPTIDE FOR TREATMENT OF FIBROPROLIFERATIVE VASCULAR DISEASES | Kither Biotech S.r.l. | COFFA, SERGIO | 1658 | DPOther | Final Rejection | — | Pending | Nov 23, 2022 |
| 17926921 | System for Localization of Anatomical Sites | The Regents of the University of California | POPESCU, GABRIEL VICTOR | 3797 | §103 | Non-Final OA | 28d | Pending | Nov 21, 2022 |
| 17921739 | Methods for Generating Thymic Cells in Vitro | The Regents of the University of California | TRAN, KHOA NHAT | 1632 | §103 | Final Rejection | — | Pending | Oct 27, 2022 |
| 17913540 | Compositions and Methods for Treatment | The Regents of the University of California | GRABER, JAMES J | 1631 | §103 | Final Rejection | — | Pending | Sep 22, 2022 |
| 17912382 | Method for Estimating Molecular Complexity | The University Court of the University of Glasgow | XU, XIAOYUN | 1797 | §103 | Final Rejection | — | Pending | Sep 16, 2022 |
| 17904565 | Adeno-Associated Viral (AAV)-Mediated Sgpl1 Gene Therapy For Treatment Of Sphingosine-1-Phosphate Lyase Insufficiency Syndrome (SPLIS) | The Regents of the University of California | PENNINGTON, KATIE LEIGH | 1634 | §103 | Final Rejection | 14d | Pending | Aug 18, 2022 |
| 17794750 | DETECTING GUT BARRIER DYSFUNCTION AND/OR CIRRHOSIS | Macfarlane Burnet Institute For Medical Research And Public Health Limited | LUSI, ELLIS FOLLETT | 1677 | §103 | Final Rejection | 9d overdue | Pending | Jul 22, 2022 |
| 17848313 | SYSTEMS AND METHODS FOR TARGETING CANCER CELLS | The Simons Foundation, Inc. | SKELDING, ZACHARY S | 1644 | §103 | Non-Final OA | 63d | Pending | Jun 23, 2022 |
| 17745399 | NANOPORE SENSOR FOR ENZYME-MEDIATED PROTEIN TRANSLOCATION | The Regents of the University of California | MINCHELLA, KAITLYN L | 1685 | DP | Final Rejection | — | Pending | May 16, 2022 |
| 17773414 | MrgprX2 Antagonists and Uses Thereof | Dermira, Inc. | HEITMEIER, KENDALL NICOLE | 1621 | §102 | Non-Final OA | 23d | Pending | Apr 29, 2022 |
| 17772467 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | Dermira, Inc. | WELLS, LAUREN QUINLAN | 1622 | §102 | Final Rejection | 30d overdue | Pending | Apr 27, 2022 |
| 17769712 | USE OF MOG FOR PRIMING A TREATMENT FOR GLIOBLASTOMA | The Regents of the University of California | DHAR, MATASHA | 1632 | §103 | Non-Final OA | 55d | Pending | Apr 15, 2022 |
| 17642089 | ANTI-ONCOLYTIC VIRUS ANTIGEN ANTIBODIES AND METHODS OF USING SAME | UVIC INDUSTRY PARTNERSHIPS INC. | PATTERSON, SARAH COOPER | 1675 | Other | Final Rejection | 46d | Pending | Mar 10, 2022 |
| 17684256 | METHODS OF PRODUCING NUCLEIC ACID LIBRARIES | The Regents of the University of California | CROW, ROBERT THOMAS | 1683 | §112 | Non-Final OA | 30d | Pending | Mar 01, 2022 |
| 17633749 | Neurofeedback Training to Promote Sharp Wave Ripples | The Regents of the University of California | ORTEGA, MARTIN NATHAN | 3791 | §112 | Final Rejection | — | Pending | Feb 08, 2022 |
| 17618870 | USE OF AMINOTHIOL COMPOUNDS AS CEREBRAL NERVE OR HEART PROTECTIVE AGENT | Shanghai Kechow Pharma, Inc. | MOORE, SUSANNA | 1624 | §103 | Non-Final OA | 55d | Pending | Dec 13, 2021 |
| 17544527 | Screening for Inhibitors of Prostaglandin E Synthase 3 Useful for Treatment of Prostate Cancer | The Regents of the University of California | RYAN, DOUGLAS CHARLES | 1635 | §103 | Non-Final OA | 12d | Pending | Dec 07, 2021 |
| 17614271 | Methods for Detecting A Mycobacterium Tuberculosis Infection | Viti, Inc. | BORGEEST, CHRISTINA M | 1675 | §112 | Final Rejection | — | Pending | Nov 24, 2021 |
| 17605198 | MODULATING SURVIVAL OF THERAPEUTIC CELLS AND METHODS, CELLS AND NUCLEIC ACIDS RELATED THERETO | The Regents of the University of California | MIANO, JOSEPH PAUL | 1631 | §103 | Non-Final OA | — | Pending | Oct 20, 2021 |
| 17490516 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | Cue Biopharma, Inc. | PATTERSON, SARAH COOPER | 1675 | Other | Final Rejection | 72d overdue | Pending | Sep 30, 2021 |
| 17459160 | Vibratory Expulsive Therapy For Urinary Stones | The Regents of the University of California | LEDERER, SARAH B | 3785 | §103 | Final Rejection | 49d overdue | Pending | Aug 27, 2021 |
| 17424055 | Methods of Treating Epilepsy via Phosphodiesterase 4 (PDE4) Inhibition | Path Therapeutics, Inc. | ROZOF, TIMOTHY R | 1625 | §112 | Final Rejection | — | Pending | Jul 19, 2021 |
| 17282319 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | The University of British Columbia | VAJDA, KRISTIN ANN | 1622 | §102 | Final Rejection | — | Pending | Apr 01, 2021 |
| 17258403 | Multimodal Neuroimaging-Based Diagnostic Systems and Methods for Detecting Tinnitus | The Regents of the University of California | KELLOGG, MICHAEL S | 3798 | §112 | Final Rejection | — | Pending | Jan 06, 2021 |
| 17258039 | Biomolecule Coated Particles and Films and Uses Thereof | The Regents of the University of California | JOHNSON, ALLISON MARIE | 1638 | §103 | Non-Final OA | — | Pending | Jan 05, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial